CLINICAL TRIAL SUMMARY

MDACC Study No:2010-0785 (clinicaltrials.gov NCT No: NCT01218477)
Title:Dasatinib (BMS-354825) combined with SMO inhibitor (BMS-833923;
XL139) in CML with resistance or suboptimal response to a prior TKI
Principal Investigator:Jorge Cortes
Treatment Agent:BMS-833923; Dasatinib
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn the highest tolerable dose
of the combination of dasatinib and BMS-833923 that can be given to patients
with CML. Researchers also want to learn about any effects the study drug
combination may have on the disease.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:BMS-833923
Dasatinib
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Bristol-Myers Squibb, Inc.
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
Dept:Leukemia
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults